

This product was created through a collaboration of the State of California Department of Public Health, Tuberculosis Control Branch (CDPH), the Rutgers Ernest Mario School of Pharmacy (EMSOP), the Rutgers Global Tuberculosis Institute (GTBI), and the Curry International Tuberculosis Center, UCSF (CITC)

Release Date: December 2022

This guide summarizes drug-drug interactions (DDI) between drugs commonly used in primary care and rifamycins, in the context of treatment of latent tuberculosis infection (LTBI).

In this table form DDI guide, drugs are grouped by class; medical providers can access clinical recommendations for each drug and compare drug options within the same drug class.

For treatment of active tuberculosis disease, or if you have additional questions regarding LTBI therapy or DDI, please consult an infectious diseases specialist, your local public health department, or your regional TB Center of Excellence.

New Educational Product Available Online!

<http://tiny.ucsf.edu/A9ISMK>



UCSF



UCSF
University of California
San Francisco

Curry International
Tuberculosis
Center

CDPH
California
Department of
Public Health

TB free
California

RUTGERS
Global Tuberculosis
Institute

RUTGERS
Ernest Mario School
of Pharmacy

Rifamycin Drug-Drug Interactions

A Guide for Primary Care
Providers Treating Latent
Tuberculosis Infection

